Gerresheimer has published its 2025 annual and consolidated financial statements, which received an unqualified audit opinion after a delay due to internal investigations into revenue recognition and accounting practices. Group revenues rose 16.6% to 2.321 billion euros, driven by the first-time consolidation of Bormioli Pharma, while adjusted EBITDA reached 384.0 million euros, down from an adjusted 388.0 million euros in 2024. The adjusted EBITDA margin, taking currency adjustments into account, stood at 16.8% compared to an adjusted pro forma 19.4% in the prior year. Organic growth was led by the Plastics & Devices division, particularly strong demand for drug delivery devices, while the Primary Packaging Glass division saw declines due to subdued demand in cosmetics and pharmaceutical oral liquids. For 2026, Gerresheimer expects revenues in the lower half of the 2.3 to 2.4 billion euro range and an adjusted EBITDA margin between 17 and 18%.
Gerresheimer AGPublished 2025 financials with 16.6% revenue rise and unqualified audit opinion, resolving accounting investigation overhang.
First-time consolidation of Bormioli Pharma contributed to revenue growth, but no standalone financial details.